Showing 2644 results
- Key Release /Cosentyx narrowly missed statistical significance for superiority in ACR 20, the primary endpoint of the EXCEED trial, while showing numerically higher results versus Humira®*[1] Statistically…
- Key Release /FDA placed a partial hold on AVXS-101 intrathecal clinical trials for SMA patients based on findings in a small pre-clinical animal studyAdverse events that might be expected from the pre-clinical…
- Media Release /New Cosentyx® (secukinumab) label to include 300 mg up-titration option is informed by results from the Phase III MEASURE 3 study[1] Approval provides clinicians with greater choice for their…
- Key Release /Continuing operations2 net sales up 13% (cc1, +10% USD) driven by: Cosentyx sales of USD 937 million (+27% cc), with strong demand across indications and regionsEntresto USD 430 million (+61% cc…
- Media Release /Decision follows FDA request for additional information to complement submission for biosimilar rituximab Sandoz stands behind safety, efficacy and quality of our biosimilar rituximab, which is…
- Media Release /Additional analysis from pivotal Phase III SOLAR-1 clinical trial studying investigational alpha-specific PI3K inhibitor BYL719 (alpelisib) and fulvestrant in patients with PIK3CA-mutated HR+/HER2-…
- Media Release /Biosimilar HyrimozTM (adalimumab-adaz) approved for all indications of reference medicine not protected by orphan exclusivity **Biosimilars are critical to sustaining US healthcare system, providing…
- Media Release /Late-breaking NATALEE subgroup analysis to be presented at ESMO shows invasive disease-free survival (iDFS) benefit remains consistent in all subgroups, including in patients with stage II tumors,…
- Media Release /Agreement includes a clinical trial to evaluate a combination of tropifexor (LJN452) and one or more Pfizer compounds for the treatment of non-alcoholic steatohepatitis (NASH) Novartis has…
- Media Release /Year two results consistent with previously announced key secondary endpoint data on retinal fluid (IRF and/or SRF) showing superior reductions versus aflibercept Superior reductions in…
Pagination
- ‹ Previous page
- 1
- …
- 196
- 197
- 198
- 199
- 200
- 201
- 202
- …
- 265
- › Next page